|
Market Closed -
Nasdaq
23:00:00 25/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 9.830 USD | +1.55% |
|
+1.34% | +26.03% |
| 08-25 | BioCryst Pharmaceuticals Announces Approval Of ORLADEYO For Pediatric HAE Patients In Japan | CI |
| 08-25 | BioCryst Pharmaceuticals Gets Japan Approval for Orladeyo in Young Children | MT |
| Market Cap | 2.51B 2.15B 2.02B 1.84B 3.48B 239B 3.51B 23.79B 9.26B 121B 9.43B 9.23B 400B | P/E 2026 * |
-4.28x | P/E 2027 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise Value | 2.51B 2.15B 2.02B 1.84B 3.48B 239B 3.51B 23.79B 9.26B 121B 9.43B 9.23B 400B | EV / Sales 2026 * |
3.58x | EV / Sales 2027 * | 3.41x |
| Free-Float |
94.77% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | +1.55% | ||
| 1 week | +1.34% | ||
| Current month | +9.47% | ||
| 1 month | +5.25% | ||
| 3 months | +18.58% | ||
| 6 months | +30.20% | ||
| Current year | +26.03% |
| 1 week | 9.48 |  | 9.99 |
| 1 month | 8.76 | | 10.68 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 01/01/2026 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 07/07/2025 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 06/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 01/01/2007 |
Theresa Heggie
BRD | Director/Board Member | 64 | 03/12/2018 |
Charles Gayer
BRD | Director/Board Member | 55 | 01/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/27/26 A | Free | Chairman | 848 | 0.0003% | ||
| 2/27/26 A | Free | Director | 1,285 | 0.0005% | ||
| 2/27/26 A | Free | Director | 528 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.55% | +1.34% | +17.16% | +35.77% | 2.51B | |
| +3.31% | -3.70% | +61.03% | +103.64% | 71.35B | |
| +1.84% | +2.10% | +49.68% | +90.80% | 64.17B | |
| +1.09% | +22.96% | +8.55% | -3.03% | 28.65B | |
| -0.07% | -3.56% | -3.45% | +467.26% | 27.06B | |
| -2.78% | +5.95% | +55.58% | +12.15% | 27.33B | |
| -0.93% | +1.30% | +38.19% | -17.11% | 20.47B | |
| +1.02% | +6.43% | +269.42% | +420.34% | 19.36B | |
| -0.57% | -0.57% | +7.19% | +538.65% | 15.96B | |
| +3.98% | +6.78% | +49.66% | +157.94% | 14.05B | |
| Average | +0.85% | +3.75% | +55.30% | +180.64% | 29.09B | |
| Weighted average by Cap. | +1.25% | +3.26% | +55.23% | +154.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 702M 602M 564M 515M 972M 66.95B 982M 6.65B 2.59B 33.78B 2.64B 2.58B 112B | 737M 632M 592M 541M 1.02B 70.29B 1.03B 6.98B 2.72B 35.46B 2.77B 2.71B 117B |
| Net income | -579M -496M -465M -424M -801M -55.18B -809M -5.48B -2.13B -27.84B -2.17B -2.13B -92.19B | 184M 158M 148M 135M 255M 17.58B 258M 1.75B 680M 8.87B 693M 677M 29.38B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | $9.830 | +1.55% | 2,332,655 |
| 24/08/26 | $9.680 | +1.36% | 2,010,324 |
| 21/08/26 | $9.550 | -1.14% | 2,496,708 |
| 20/08/26 | $9.660 | -4.07% | 2,329,247 |
| 19/08/26 | $10.07 | +3.81% | 2,906,761 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
